Pomerantz Law Firm Announces Class Action Lawsuit Against Erasca, Inc.
A class action lawsuit has been filed against Erasca (NASDAQ: ERAS) over alleged securities fraud and unlawful business practices. The firm also disclosed a patent infringement claim from Revolution Medicines and the death of one patient in its clinical trial for ERAS-0015, leading to a 10.7% drop in stock price.
Topics: clinical trial data patent infringement securities fraud